medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 6

Next >>

Ann Hepatol 2013; 12 (6)

Treatment of chronic hepatitis C virus infection in the near future

Cheinquer H

Language: English
References: 33
Page: 854-859
PDF size: 90.98 Kb.


Text Extraction

INTRODUCTION
Hepatitis C virus (HCV) is currently the most important cause of cirrhosis and hepatocellular carcinoma in the Western World. Remarkably, HCV is probably the only chronic human viral infectious agent that can be completely eradicated. Indeed, the occurrence of a sustained virological response (SVR) is almost always equivalent to a cure of the infection.


REFERENCES

  1. EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatology 2011; 55: 245-64.

  2. Ghany MG, Nelson DR, Strader DB, et al. An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.

  3. Manns MP, Pockros PJ, Norkrans G, et al. Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. J Viral Hepat 2013; 20: 524-9.

  4. Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010; 51: 2069-76.

  5. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44.

  6. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.

  7. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.

  8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.

  9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

  10. Hadziyannis SJ, Sette H Jr., Morgan TR, et al. Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.

  11. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.

  12. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.

  13. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.

  14. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.

  15. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56(Suppl. 1): S88-S100.

  16. A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013: The 48th Annual Meeting of the European Association for the Study of the LiverApril 24-28, 2013 • Amsterdam, The NetherlandsSpecial Reporting on:• Simeprevir Plus Peginterferon/ Ribavirin Is Associated with a High SVR12 Rate in Treatment-Naive Patients with Genotype 1 Hepatitis C Virus Infection• Addition of Simeprevir to Peginterferon/Ribavirin Is Associated with Faster Resolution of Fatigue in Treatment-Naive Patients• Sofosbuvir Plus Ribavirin Demonstrates Significant Efficacy in Multiple HCV Genotype 2/3 Populations• Daclatasvir Plus Sofosbuvir with or without Ribavirin Yields 100% SVR24 Rate in Genotype 1 Patients Who Fail Telaprevir or Boceprevir• Addition of TG4040 Vaccine to Peginterferon/Ribavirin Increases Sustained Virologic Response Rate at 24 Weeks in Genotype 1 Hepatitis C InfectionPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDJoan Sanford I. Weill Medical College at Cornell UniversityNew York, New York. Gastroenterol Hepatol (NY) 2013; 9(Suppl. 3): 1-18.

  17. Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. Presented at the 48th Annual Meeting of the European Association for the Study of the Liver; April 24–28, 2013; Amsterdam, the Netherlands. Abstract 1525.

  18. Manns M, Marcellin P, Poordad FP, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment- naive patients: results from QUEST-2, a phase III trial. Presented at the 48th Annual Meeting of the European Association for the Study of the Liver; April 24–28, 2013; Amsterdam, the Netherlands. Abstract 1413.

  19. Zeuzem S, Berg T, Gane E, et al. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon/ ribavirin treatment: final SVR24 results of the ASPIRE trial. Presented at the 47th Annual Meeting of the European Association for the Study of the Liver; April 18–22, 2012; Barcelona, Spain. Abstract 2.

  20. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.

  21. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.

  22. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.

  23. Lawitz E, Ghalib R, Rodriguez-Torres M, et al. Suppression of Viral Load through 4 Weeks Post-Treatment Results of a Once-daily Regimen of Simeprevir + Sofosbuvir with or without Ribavirin in Hepatitis C Virus GT 1 Null Responders. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 155LB.

  24. Ferenci P, Asselah T, Foster GR, et al. Falaprevir plus pegylated interferon alfa2a and ribavirin in chronic HCV genotype- 1 treatment-naïve patients: Final results from STARTVERSO1, a randomized, placebo-controlled phase III trial. 48th Annual Meeting of the European Association for the Study of the Liver, April 24-28, 2013, Amsterdam, Netherlands; abstract 1416.

  25. Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-9.

  26. Kowdley KV, Lawitz E, Poordad F, et al. A 12-week interferon- free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR rates (observed data) of 99% in treatment-naïve patients and 93% in prior null responders with HCV genotype 1 infection. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012). Boston, November 9-13, 2012. Abstract LB-1.

  27. Gane E, Stedman CA, Hyland RH, et al. All-oral sofosbuvirbased 12-week regimens for the treatment of chronic HCV infection: the ELECTRON study. 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013). Amsterdam. April 24-28, 2013. Abstract 14.

  28. Hezode C, Hirschfield G, Ghesquiere W, et al. Daclatasvir, an NS5A Replication Complex Inhibitor, Combined With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive HCVGenotype 1 or 4 Patients: Phase 2b COMMAND-1 SVR12 Results. Hepatology 2012; 56(Suppl. 1): 553A. Abstract 755.

  29. Dore GJ, Lawitz E, Hezode C, et al. Daclatasvir combined with peginterferon alfa 2a alfa-and ribavirin for 12 or 16 weeks in patients with hepatitis c virus genotype 2 or 3 infection: command gt 2/3 study. Presented at the 48th Annual Meeting of the European Association for the Study of the Liver; April 24–28, 2013; Amsterdam, the Netherlands. Abstract 1418.

  30. Everson GT, Sims KD, Rodriguez-Torres M, et al. Interim analysis of an interferon (IFN)- and ribavirin (RBV)-free regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS- 791325 in treatment-naive, hepatitis C virus genotype 1- infected patients. Presented at the 48th Annual Meeting of the European Association for the Study of the Liver; April 24–28, 2013; Amsterdam, the Netherlands. Abstract 1417.

  31. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naïve patients chronically infected with HCG GT 1, 2, or 3. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases; November 9–13, 2012; Boston, Massachusetts. Abstract LB-2.

  32. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Sustained virologic response with daclatasvir plus sofosbuvir plus/minus ribavirin (RBV) in chronic HCV genotype (GT) 1- infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). Presented at the 48th Annual Meeting of the European Association for the Study of the Liver; April 24–28, 2013; Amsterdam, the Netherlands. Abstract 1417.

  33. Shakespeare W. Henry V (act 3, scene 1).




2020     |     www.medigraphic.com